News
CPIX
2.398
+2.93%
0.068
Newpark Resources And 2 Other Penny Stocks Insiders Are Aggressively Buying
Benzinga · 11/21 14:06
BRIEF-Cumberland Pharmaceuticals Reports 41% Revenue Growth
Reuters · 11/08 23:28
Cumberland Pharmaceuticals Non-GAAP EPS of $0.10, revenue of $11.41M
Seekingalpha · 11/08 21:51
Cumberland Q3 Adj. EPS $0.10 Up From $(0.02) YoY, Sales $11.41M Up From $8.07M YoY
Benzinga · 11/08 21:16
-- Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Posts Q3 Revenue $11.4M
-- Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Posts Q3 Revenue $11.4M
MT Newswires · 11/08 16:51
-- Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q3 EPS $0.10
-- Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q3 EPS $0.10
MT Newswires · 11/08 16:50
CUMBERLAND PHARMACEUTICALS MOVES INTO NEW HEADQUARTERS AT BROADWEST
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), the largest, public biopharmaceutical company founded and headquartered in Tennessee, announced today that it has moved its headquarters to the Broadwest campus in the Vanderbilt/West End corridor of Nashvill...
PR Newswire · 11/01 13:20
$3 Million Bet On This Communication Services Stock? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones dropped more than 290 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 08/22 15:08
Cumberland Q2 EPS $(0.01), Sales $10.30M Beat $9.19M Estimate
Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.01) per share. The company reported quarterly sales of $10.30 million which beat the analyst consensus estimate of $9.19 million by 12.08 percent. This is a
Benzinga · 08/09 21:17
Cumberland Pharmaceuticals Non-GAAP EPS of -$0.01, revenue of $10.3M
Cumberland Pharmaceuticals press release (...
Seekingalpha · 08/09 20:38
-- Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q2 Revenue $10.3M
-- Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q2 Revenue $10.3M
MT Newswires · 08/09 16:21
Cumberland Pharmaceuticals Reports 2.4m Patient Doses Delivered, No Product Recalls, No FDA Issues In 2021
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today released its 2021 Sustainability Report detailing its activities regarding its involvement in environmental, social and governance
Benzinga · 08/08 13:26
CUMBERLAND PHARMACEUTICALS REPORTS 2.4M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2021
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today released its 2021 Sustainability Report detailing its activities regarding its involvement in environmental, social and governance matters.
PR Newswire · 08/08 13:25
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2022 financial results and provide a company update after the market closes on Tuesday, Aug. 9, 2022.
PR Newswire · 08/02 20:05
BRIEF-Cumberland Pharmaceuticals Appoints Martin Brown Jr. To Board
BRIEF-Cumberland Pharmaceuticals Appoints Martin Brown Jr. To Board
Reuters · 07/19 13:32
Stocks That Hit 52-Week Lows On Monday
  On Monday, 149 companies reached new 52-week lows.
Benzinga · 05/23 16:12
Estimating The Intrinsic Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)
Does the May share price for Cumberland Pharmaceuticals Inc. ( NASDAQ:CPIX ) reflect what it's really worth? Today, we...
Simply Wall St. · 05/13 16:27
Cumberland Pharmaceuticals Non-GAAP EPS of $0.03, revenue of $11.2M
Cumberland Pharmaceuticals press release (NASDAQ:CPIX): Q1 Non-GAAP EPS of $0.03. Revenue of $11.2M (+6.3% Y/Y). Shares +1.95% AH.
Seekingalpha · 05/10 21:02
Cumberland Q1 Adj. EPS $0.03 Down From $0.07 YoY, Sales $11.20M Up From $10.54M YoY
Cumberland (NASDAQ:CPIX) reported quarterly earnings of $0.03 per share. This is a 57.14 percent decrease over earnings of $0.07 per share from the same period last year. The company reported $11.20 million in sales
Benzinga · 05/10 20:42
-- Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Posts Q1 Revenue $11.2M
MT Newswires · 05/10 16:27
More
Webull provides a variety of real-time CPIX stock news. You can receive the latest news about Cumberland Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CPIX
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that is focused on the acquisition, development, and commercialization of prescription pharmaceutical products. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever; Kristalose for oral solution, a prescription laxative, for the treatment of constipation; and Omeclamox-Pak for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease. Its brands also include RediTrex injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis; Sancuso transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ injection.